JP2022513299A5 - - Google Patents
Info
- Publication number
- JP2022513299A5 JP2022513299A5 JP2021534939A JP2021534939A JP2022513299A5 JP 2022513299 A5 JP2022513299 A5 JP 2022513299A5 JP 2021534939 A JP2021534939 A JP 2021534939A JP 2021534939 A JP2021534939 A JP 2021534939A JP 2022513299 A5 JP2022513299 A5 JP 2022513299A5
- Authority
- JP
- Japan
- Prior art keywords
- bifunctional molecule
- molecule according
- bifunctional
- m6pr
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024212140A JP2025041675A (ja) | 2018-12-19 | 2024-12-05 | リソソーム標的化のための二官能性分子ならびに関連する組成物および方法 |
| JP2026010986A JP2026090304A (ja) | 2018-12-19 | 2026-01-27 | リソソーム標的化のための二官能性分子ならびに関連する組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782193P | 2018-12-19 | 2018-12-19 | |
| US62/782,193 | 2018-12-19 | ||
| US201962932347P | 2019-11-07 | 2019-11-07 | |
| US62/932,347 | 2019-11-07 | ||
| PCT/US2019/067228 WO2020132100A1 (en) | 2018-12-19 | 2019-12-18 | Bifunctional molecules for lysosomal targeting and related compositions and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024212140A Division JP2025041675A (ja) | 2018-12-19 | 2024-12-05 | リソソーム標的化のための二官能性分子ならびに関連する組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022513299A JP2022513299A (ja) | 2022-02-07 |
| JP2022513299A5 true JP2022513299A5 (enExample) | 2022-12-26 |
| JP7674740B2 JP7674740B2 (ja) | 2025-05-12 |
Family
ID=71102305
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021534939A Active JP7674740B2 (ja) | 2018-12-19 | 2019-12-18 | リソソーム標的化のための二官能性分子ならびに関連する組成物および方法 |
| JP2024212140A Pending JP2025041675A (ja) | 2018-12-19 | 2024-12-05 | リソソーム標的化のための二官能性分子ならびに関連する組成物および方法 |
| JP2026010986A Pending JP2026090304A (ja) | 2018-12-19 | 2026-01-27 | リソソーム標的化のための二官能性分子ならびに関連する組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024212140A Pending JP2025041675A (ja) | 2018-12-19 | 2024-12-05 | リソソーム標的化のための二官能性分子ならびに関連する組成物および方法 |
| JP2026010986A Pending JP2026090304A (ja) | 2018-12-19 | 2026-01-27 | リソソーム標的化のための二官能性分子ならびに関連する組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20220023434A1 (enExample) |
| EP (1) | EP3897747A4 (enExample) |
| JP (3) | JP7674740B2 (enExample) |
| KR (1) | KR20210104828A (enExample) |
| CN (1) | CN113301925A (enExample) |
| AU (1) | AU2019404061B2 (enExample) |
| BR (1) | BR112021012113A2 (enExample) |
| CA (1) | CA3123086A1 (enExample) |
| IL (1) | IL283958B1 (enExample) |
| MX (1) | MX2021007376A (enExample) |
| SG (1) | SG11202106209RA (enExample) |
| WO (1) | WO2020132100A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12485178B2 (en) | 2018-04-09 | 2025-12-02 | Yale University | Bifunctional small molecules to target the selective degradation of circulating proteins |
| US12697391B2 (en) | 2018-04-09 | 2026-08-04 | Yale University | Bi-functional molecules to degrade circulating proteins |
| CA3134610A1 (en) | 2018-04-09 | 2019-10-17 | Yale University | Bifunctional small molecules to target the selective degradation of circulating proteins |
| EP3897747A4 (en) | 2018-12-19 | 2022-12-07 | The Board of Trustees of the Leland Stanford Junior University | BIFUNCTIONAL MOLECULES FOR LYSOSOMA TARGETING AND RELATED COMPOSITIONS AND METHODS |
| US20240342293A1 (en) * | 2019-10-10 | 2024-10-17 | Yale University | Engineered antibodies as molecular degraders through cellular receptors |
| US20250269043A1 (en) * | 2019-10-10 | 2025-08-28 | Yale University | Targeted bifunctional degraders |
| EP4081241A4 (en) | 2019-12-24 | 2024-05-01 | Juvena Therapeutics, Inc. | REGENERATIVE POLYPEPTIDES AND USES THEREOF |
| MX2022009419A (es) | 2020-01-31 | 2022-08-25 | Avilar Therapeutics Inc | Compuestos de union al asgpr para la degradacion de proteinas extracelulares. |
| AU2021225962A1 (en) | 2020-02-28 | 2022-10-20 | Genzyme Corporation | Modified binding polypeptides for optimized drug conjugation |
| WO2022006113A1 (en) * | 2020-06-30 | 2022-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Cis-binding siglec agonists and related compositions and methods |
| WO2022035997A1 (en) * | 2020-08-11 | 2022-02-17 | Avilar Therapeutics, Inc. | In vivo assembly of asgpr binding therapeutics |
| CN114438088B (zh) * | 2020-11-03 | 2025-05-23 | 韩达 | 一种溶酶体靶向的核酸嵌合体的制备及应用 |
| EP4281115A1 (en) * | 2021-01-19 | 2023-11-29 | Novartis AG | Degradation of extracellular targets |
| CN114573714B (zh) * | 2021-03-15 | 2023-03-31 | 北京大学 | 用于靶分子修饰的缀合物及其制备方法 |
| US20240182584A1 (en) * | 2021-04-02 | 2024-06-06 | The Board Of Trustees Of The Leland Stanford Junior University | Bispecific Molecules and Related Compositions and Methods |
| AU2022268925A1 (en) * | 2021-05-03 | 2023-11-16 | Avilar Therapeutics, Inc. | Potent asgpr-binding compounds for the degradation of immunoglobulins and other proteins |
| EP4359425B1 (en) | 2021-06-21 | 2026-08-05 | Juvena Therapeutics, Inc. | Igf2 fusion polypeptide and use in the treatment of muscular dystrophy, sarcopenia, cachexia, or muscle injury |
| EP4359430A4 (en) * | 2021-06-23 | 2025-07-16 | Lycia Therapeutics Inc | BIFUNCTIONAL COMPOUNDS CONTAINING IGF-2 POLYPEPTIDES |
| CN117915956A (zh) | 2021-07-14 | 2024-04-19 | 利西亚治疗公司 | M6pr细胞表面受体结合化合物和缀合物 |
| JP2024524614A (ja) | 2021-07-14 | 2024-07-05 | ライシア セラピューティクス， インコーポレイテッド | Ａｓｇｐｒ細胞表面受容体結合化合物及びコンジュゲート |
| EP4377352A2 (en) * | 2021-07-30 | 2024-06-05 | Vib Vzw | Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation |
| CN117343197A (zh) * | 2021-10-15 | 2024-01-05 | 中山大学 | 重组融合抗体 |
| CN114522244B (zh) * | 2022-01-28 | 2023-09-01 | 浙江大学医学院附属第四医院 | 视黄酸修饰的lytac分子及其制备方法和应用 |
| FR3132634B1 (fr) * | 2022-02-15 | 2025-04-25 | Nanomedsyn | Composés bifonctionnels ciblant le récepteur du mannose 6-phosphate cation-indépendant |
| JP2025509736A (ja) * | 2022-03-15 | 2025-04-11 | イエール ユニバーシティ | 循環タンパク質を分解するための二官能性分子 |
| JP2025509730A (ja) * | 2022-03-15 | 2025-04-11 | イエール ユニバーシティ | 循環タンパク質の選択的分解を目的とした二官能性小分子 |
| WO2023183413A2 (en) * | 2022-03-22 | 2023-09-28 | Wisconsin Alumni Research Foundation | Transferrin-based lysosome targeting degraders |
| US20250345446A1 (en) * | 2022-06-23 | 2025-11-13 | Draupnir Bio Aps | Bifunctional molecules that selectively induce degradation of extracellular targets in lysosomes |
| WO2024003300A1 (en) * | 2022-06-30 | 2024-01-04 | Aptadegrad, S.L. | Dna aptamer conjugates recognizing and degrading coronavirus proteins |
| GB202211100D0 (en) * | 2022-07-29 | 2022-09-14 | Stam Jord Cornelis | Lysosomal degradation |
| EP4569000A4 (en) * | 2022-08-12 | 2026-07-15 | Lycia Therapeutics Inc | Bispecific antibodies and constructions for lysosomal targeting degradation and their methods of use |
| GB202212077D0 (en) | 2022-08-18 | 2022-10-05 | Tribune Therapeutics Ab | Agents that inhibit ccn ligand-induced signalling for treating disease |
| JP2025534987A (ja) * | 2022-09-28 | 2025-10-22 | グリコエラ アーゲー | グリカン媒介タンパク質分解 |
| JP2026513101A (ja) | 2022-10-25 | 2026-04-23 | アブリンクス エン．ヴェー． | エフェクター機能が強化された糖鎖改変Ｆｃ変異ポリペプチド |
| AU2023367846A1 (en) * | 2022-10-26 | 2025-05-01 | Amgen Inc. | Multispecific molecules for clearance of immunoglobulins in the treatment of autoantibody-induced diseases |
| WO2024155748A1 (en) | 2023-01-18 | 2024-07-25 | Lycia Therapeutics, Inc. | M6pr binding compounds and conjugates |
| WO2024182772A2 (en) * | 2023-03-02 | 2024-09-06 | Avilar Therapeutics, Inc. | Mannose 6-phosphate receptor binding compounds for the degradation of extracellular proteins |
| CN118697896A (zh) * | 2023-03-27 | 2024-09-27 | 中山大学 | 嵌合体在靶向蛋白质降解技术中的应用 |
| PL445164A1 (pl) * | 2023-06-07 | 2024-12-09 | Recepton Spółka Z Ograniczoną Odpowiedzialnością | Cząsteczki indukujące internalizację receptorów i białek zewnątrzkomórkowych |
| WO2025133234A1 (en) * | 2023-12-22 | 2025-06-26 | Draupnir Bio Aps | Sortilin binders and bifunctional compounds thereof |
| CN122514544A (zh) * | 2024-01-05 | 2026-08-04 | 株式会社绿十字 | 用于溶酶体降解的多特异性抗体 |
| WO2025189160A1 (en) * | 2024-03-08 | 2025-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Trogocytosis-inducing bispecific molecules and methods of use |
| WO2025238106A1 (en) | 2024-05-15 | 2025-11-20 | M6P Therapeutics (Switzerland) GmbH | Lysosome-targeting degradation fusion design |
| WO2026017888A1 (en) * | 2024-07-18 | 2026-01-22 | Universiteit Gent | Targeted protein degradation and recruitment |
| WO2026019282A1 (ko) * | 2024-07-18 | 2026-01-22 | 한국생명공학연구원 | 라이소좀 타겟팅 키메라, 이의 제조 방법 및 이를 포함하는 약학 조성물 |
| CN120393039A (zh) * | 2024-11-01 | 2025-08-01 | 珠海市睿森生物科技有限公司 | 一种多肽药物嵌合体及其制备方法 |
| WO2026120177A1 (en) | 2024-12-06 | 2026-06-11 | Ascendis Pharma A/S | Novel long-acting degrader conjugates |
| CN121550444A (zh) * | 2025-12-04 | 2026-02-24 | 中国人民解放军军事科学院军事医学研究院 | 一种治疗急性肝衰竭的新型TNF-α靶向蛋白降解剂 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2752892A (en) | 1991-09-26 | 1993-04-27 | Oklahoma Medical Research Foundation | Fusion proteins targeted to lysosomes, for the treatment of aids |
| DK129293D0 (da) | 1993-11-16 | 1993-11-16 | Carlsberg Lab | Carbonhydratholdige forbindelser, der kan binde sig til carbonhydratbindende receptorer |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| CA2318981A1 (en) * | 1998-02-09 | 1999-08-12 | Genzyme Corporation | Nucleic acid delivery vehicles |
| US6093382A (en) | 1998-05-16 | 2000-07-25 | Bracco Research Usa Inc. | Metal complexes derivatized with folate for use in diagnostic and therapeutic applications |
| AU770340B2 (en) | 1998-10-08 | 2004-02-19 | Biorion Technologies B.V. | Peptide-based carrier devices for stellate cells |
| US6426208B1 (en) | 1999-11-12 | 2002-07-30 | Harbor-Ucla Research And Education Institute | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
| US20040009907A1 (en) | 2001-02-26 | 2004-01-15 | Alsobrook John P. | Proteins and nucleic acids encoding same |
| WO2001080883A1 (en) * | 2000-04-26 | 2001-11-01 | Elusys Therapeutics, Inc. | Bispecific molecules and uses thereof |
| NZ524980A (en) | 2000-09-01 | 2005-10-28 | Biogen Idec Inc | Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications |
| ES2404689T3 (es) | 2001-04-05 | 2013-05-28 | The Johns Hopkins University | Vacunas quiméricas que comprenden el dominio lumenal de LAMP-1 o LAMP-2 |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US20030049203A1 (en) | 2001-08-31 | 2003-03-13 | Elmaleh David R. | Targeted nucleic acid constructs and uses related thereto |
| EP2292273A3 (en) * | 2001-10-10 | 2011-11-23 | BioGeneriX AG | Remodeling and glycoconjugation of peptides |
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| US20050191309A1 (en) | 2002-05-06 | 2005-09-01 | Kakkis Emil D. | Induction of antigen specific immunologic tolerance |
| US7485314B2 (en) | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
| AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| PT1628987E (pt) | 2003-05-20 | 2009-10-29 | Pharmaxis Pty Ltd | Compostos manose-6-fosfonato para o tratamento de doenças inflamatórias |
| US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| WO2006007560A2 (en) | 2004-07-01 | 2006-01-19 | University Of Pennsylvania | Targeted protein replacement for the treatment of lysosomal storage disorders |
| GB0423405D0 (en) | 2004-10-21 | 2004-11-24 | Novartis Ag | Organic compounds |
| EP1745802A1 (en) | 2005-07-20 | 2007-01-24 | Kreatech Biotechnology B.V. | Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes |
| US20070104648A1 (en) | 2005-11-09 | 2007-05-10 | Glyconix Corporation | Compositions, methods of preparing amino acids, and nuclear magnetic resonance spectroscopy |
| EP2009990B1 (en) | 2006-04-07 | 2016-09-21 | The Board of Regents of The University of Texas System | Methods and compositions related to adenoassociated virus-phage particles |
| US20080057072A1 (en) | 2006-08-31 | 2008-03-06 | Alcon Manufacturing, Ltd. | Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disorders |
| JP5244810B2 (ja) | 2006-11-10 | 2013-07-24 | カラ セラピューティクス インコーポレイテッド | 合成ペプチドアミド |
| WO2008089339A2 (en) * | 2007-01-18 | 2008-07-24 | Genzyme Corporation | Oligosaccharide conjugates for cellular targeting |
| JP5675619B2 (ja) | 2008-09-17 | 2015-02-25 | エンドサイト, インク.Endocyte, Inc. | 葉酸拮抗薬の葉酸受容体結合性コンジュゲート |
| EP3608330B1 (en) * | 2008-12-16 | 2022-11-09 | Genzyme Corporation | Synthetic intermediates for preparing oligosaccharide-protein conjugates |
| JP2012525369A (ja) | 2009-04-28 | 2012-10-22 | ファーマキシス リミテッド | 創傷および線維性障害の治療のためのホスホテトラヒドロピラン化合物 |
| EP2448600B1 (en) * | 2009-07-03 | 2016-03-30 | INSERM - Institut National de la Santé et de la Recherche Médicale | Compounds targeting the cation-independent mannose 6-phosphate receptor |
| WO2011038234A2 (en) | 2009-09-24 | 2011-03-31 | University Of Louisville Research Foundation, Inc. | Novel iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (mif)-implicated diseases and conditions |
| FR2952372B1 (fr) | 2009-11-10 | 2012-03-23 | Centre Nat Rech Scient | Nouveaux derives de mannopyranoside ayant une activite anticancereuse |
| EP2343081A1 (en) | 2009-12-31 | 2011-07-13 | Rijksuniversiteit Groningen | Interferon analogs |
| US20120121592A1 (en) * | 2010-10-13 | 2012-05-17 | Baylor Research Institute | Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells |
| LT2714752T (lt) | 2011-05-27 | 2018-03-12 | Amicus Therapeutics, Inc. | Nukreipiančių peptidų kopuliavimo ant rekombinantinių lizosominių fermentų būdai, skirti lizosominio kaupimo ligų gydymo pagerinimui |
| SG10201704846VA (en) * | 2012-03-14 | 2017-07-28 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| WO2014022515A1 (en) | 2012-07-31 | 2014-02-06 | Bioasis Technologies, Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
| WO2014082080A2 (en) | 2012-11-26 | 2014-05-30 | Callidus Biopharma, Inc. | Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases |
| WO2014089209A2 (en) | 2012-12-04 | 2014-06-12 | Abbvie, Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins |
| JP2016514096A (ja) | 2013-02-20 | 2016-05-19 | バレリオン セラピューティクス， エルエルシー | ポンぺ病の処置のための方法および組成物 |
| WO2014178878A1 (en) | 2013-05-03 | 2014-11-06 | Yale University | Synthetic antibody mimetic compounds (syams) targeting cancer, especially prostate cancer |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| HUE061339T2 (hu) * | 2014-03-19 | 2023-06-28 | Genzyme Corp | Targetáló csoportok helyspecifikus glikotechnikai átalakítása |
| RU2696490C2 (ru) | 2014-05-19 | 2019-08-02 | Пфайзер Инк. | Замещенные-6,8-диоксабицикло[3.2.1.]октан-2,3-диольные соединения в качестве агентов, нацеленных на ASGPR |
| WO2015191934A2 (en) | 2014-06-11 | 2015-12-17 | Abbvie Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases |
| WO2016025519A1 (en) * | 2014-08-11 | 2016-02-18 | Shire Human Genetic Therapies, Inc. | Mannose-6-phosphate bearing peptides fused to lysosomal enzymes |
| US20170290806A1 (en) | 2014-09-08 | 2017-10-12 | Temple University-Of The Commonwealth System Of Higher Education | PCSK9 Inhibitors and Methods of Use Thereof |
| PL3204425T3 (pl) | 2014-10-09 | 2021-03-08 | Genzyme Corporation | Glikomodyfikowane koniugaty przeciwciał z lekami |
| US20160166679A1 (en) | 2014-12-12 | 2016-06-16 | Purdue Research Foundation | Method of treatment using folate conjugates and tyrosine kinase inhibitors |
| JP6993958B2 (ja) * | 2015-07-06 | 2022-02-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 多重特異性抗原結合分子およびその使用 |
| FR3041345B1 (fr) | 2015-09-18 | 2019-06-14 | Nanomedsyn | Composes polysaccharides multi-fonctionnalises et leur utilisation pour cibler le recepteur du mannose 6-phosphate cation-independant |
| AU2016332900C1 (en) * | 2015-09-29 | 2024-07-04 | Amgen Inc. | ASGR inhibitors |
| MY207684A (en) | 2015-12-08 | 2025-03-12 | Regeneron Pharma | Compositions and methods for internalizing enzymes |
| KR20180104148A (ko) * | 2016-02-05 | 2018-09-19 | 젠맵 에이/에스 | 개선된 내재화 특징을 갖는 다중특이적 항원-결합 분자 |
| JP7100629B2 (ja) | 2016-06-09 | 2022-07-13 | セントレ・ナショナル・デ・ラ・レシェルシェ・サイエンティフィーク | 化学修飾されたカプシドを有するｒａａｖ |
| AU2018281280B2 (en) | 2017-06-07 | 2024-12-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
| CA3134765A1 (en) | 2018-04-09 | 2019-10-17 | Yale University | Bi-functional molecules to degrade circulating proteins |
| CA3134610A1 (en) | 2018-04-09 | 2019-10-17 | Yale University | Bifunctional small molecules to target the selective degradation of circulating proteins |
| EP3897747A4 (en) | 2018-12-19 | 2022-12-07 | The Board of Trustees of the Leland Stanford Junior University | BIFUNCTIONAL MOLECULES FOR LYSOSOMA TARGETING AND RELATED COMPOSITIONS AND METHODS |
| EP3997214B1 (en) | 2019-07-11 | 2023-08-02 | Centre National de la Recherche Scientifique | Chemically-modified adeno-associated virus |
| US20240342293A1 (en) | 2019-10-10 | 2024-10-17 | Yale University | Engineered antibodies as molecular degraders through cellular receptors |
| US20250269043A1 (en) | 2019-10-10 | 2025-08-28 | Yale University | Targeted bifunctional degraders |
-
2019
- 2019-12-18 EP EP19901042.2A patent/EP3897747A4/en active Pending
- 2019-12-18 WO PCT/US2019/067228 patent/WO2020132100A1/en not_active Ceased
- 2019-12-18 BR BR112021012113-7A patent/BR112021012113A2/pt unknown
- 2019-12-18 JP JP2021534939A patent/JP7674740B2/ja active Active
- 2019-12-18 SG SG11202106209RA patent/SG11202106209RA/en unknown
- 2019-12-18 US US17/311,779 patent/US20220023434A1/en not_active Abandoned
- 2019-12-18 AU AU2019404061A patent/AU2019404061B2/en active Active
- 2019-12-18 MX MX2021007376A patent/MX2021007376A/es unknown
- 2019-12-18 KR KR1020217022461A patent/KR20210104828A/ko not_active Ceased
- 2019-12-18 CN CN201980087886.9A patent/CN113301925A/zh active Pending
- 2019-12-18 IL IL283958A patent/IL283958B1/en unknown
- 2019-12-18 CA CA3123086A patent/CA3123086A1/en active Pending
-
2021
- 2021-10-12 US US17/499,272 patent/US11787865B2/en active Active
-
2023
- 2023-09-08 US US18/244,121 patent/US20230416377A1/en active Pending
-
2024
- 2024-12-05 JP JP2024212140A patent/JP2025041675A/ja active Pending
-
2026
- 2026-01-27 JP JP2026010986A patent/JP2026090304A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7614094B2 (ja) | 薬物コンジュゲート | |
| Jones et al. | Blood–brain barrier transport of therapeutics via receptor-mediation | |
| Adhikari et al. | Antibody‐Nanoparticle conjugates in therapy: combining the best of two worlds | |
| EP2976109B1 (en) | Cellular delivery of dna intercalating agents | |
| US12146238B2 (en) | Target-specific extracellular vesicles | |
| CN107847588A (zh) | 具有靶向部分及效应部分的分子构建体及其应用 | |
| JP2023515708A5 (enExample) | ||
| WO2022271981A2 (en) | Bifunctional compounds containing igf-2 polypeptides | |
| JP2026065117A (ja) | 最適化された薬物コンジュゲーションのための改変された結合ポリペプチド | |
| EP4077377A1 (en) | Bispecific antibodies with alternatively matched interchain cysteines and uses thereof | |
| Nanaware-Kharade et al. | Therapeutic anti-methamphetamine antibody fragment-nanoparticle conjugates: synthesis and in vitro characterization | |
| CN120399078B (zh) | 靶向cd117的纳米抗体及其应用 | |
| JP7652807B2 (ja) | 単一ドメイン抗体、サポニン及びエフェクター分子のコンジュゲート、それを含む医薬組成物、前記医薬組成物の治療的使用 | |
| Ashique et al. | Nanobodies in Asthma Therapy: a Promising Frontier in Targeted Respiratory Treatment | |
| CN122028909A (zh) | 用于主动靶向的具有非共价双功能结合物的脂质纳米颗粒 | |
| Khaleghi et al. | Camelid single-domain antibodies for targeting cancer nanotheranostics | |
| US11028132B1 (en) | Half-life optimized linker composition | |
| Tian et al. | The use of peptide and protein vectors to cross the Blood-Brain barrier for the delivery of therapeutic concentration of biologics | |
| Chen et al. | Antibody‐Empowered Nanomedicine for Precise Biomedical Applications | |
| CN120399079B (zh) | 靶向cd90的纳米抗体及其应用 | |
| CN119751683B (zh) | 抗cd5纳米抗体及其在体内car细胞疗法中的应用 | |
| EP4520768A1 (en) | Vhh-ch3 fusion proteins | |
| EP4480965A1 (en) | Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat cns diseases | |
| TW202535941A (zh) | 具有特製藥物對抗體比之抗體-藥物結合物 | |
| KR102215150B1 (ko) | 경구용 유전자 전달체 및 이의 용도 |